Mission Statement, Vision, & Core Values (2026) of Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co., listed on the Shanghai Stock Exchange as 600211.SS, is turning traditional Tibetan herbal wisdom into a modern growth story by operating a fully vertically integrated supply chain from sustainable Rhodiola harvesting to R&D and global distribution, driving a reported net income of CNY 1.05 billion as of late 2025 while reinvesting roughly 10% of annual revenue into new formulations; with explicit sustainability targets-aiming for a 50% reduction in carbon footprint by 2030-and strategic ambitions to scale into North American and European markets, the company is positioned to capitalize on a global herbal supplement market that was valued at $121.6 billion in 2021 and is projected to grow at a 9.6% CAGR from 2022 to 2030, making its mission, vision, and core values central to both financial performance and long-term international expansion.

Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) - Intro

• Listed on the Shanghai Stock Exchange under the ticker symbol 600211.SS.
• Vertically integrated model: seed-to-shelf control of Rhodiola sourcing, extraction, clinical development and commercialization.
• Product focus: traditional Tibetan herbal medicines and derivative prescription and OTC products leveraging Rhodiola and other plateau botanicals.
• Market reach: significant domestic presence across hospital, pharmacy and e-commerce channels, with growing exports and cross-border partnerships targeting Asia, Europe and niche natural-remedy markets globally.

• Sustainable harvesting protocols and seed program partnerships to ensure genetic diversity and long-term yield stability.
• Investment in GMP-certified manufacturing and clinical research to support prescription product approvals and evidence-based claims.
• Expansion of export channels and regulatory alignment to capitalize on rising global demand for natural and traditional remedies.

• Robust profitability with CNY 1.05 billion net income reported in late 2025, reflecting operational efficiency in cultivation, processing and sales.
• Explicit environmental target to cut carbon emissions by 50% by 2030, with initiatives including energy-efficient processing lines, renewable energy adoption at production sites and optimization of logistics.
• Continued R&D emphasis on clinical validation of traditional formulations, formulation innovation (standardized extracts, controlled-release dosage forms) and quality-assurance technologies (traceability, contaminant testing).

Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) Overview

• Core product focus: Rhodiola rosea extracts and derivative nutraceutical formulations for stress, fatigue, and metabolic support.
• Manufacturing standards: GMP-compliant facilities and third-party testing to ensure product efficacy and safety.
• R&D commitment: Approximately 10% of annual revenue allocated to developing new formulations and clinical validation.
• Sustainability target: Committed to a 50% reduction in carbon footprint by 2030 across operations and supply chain.

• Enhance quality of life through natural health alternatives grounded in traditional Chinese herbal medicine.
• Uphold rigorous safety and efficacy standards in manufacturing and product development.
• Drive innovation with a sustained R&D budget (~10% of revenue) to expand formulation pipelines and clinical evidence.
• Pursue measurable environmental stewardship, including a 50% reduction in carbon emissions by 2030.

• R&D allocation (~10% of revenue) funds formulation innovation, clinical studies, and process improvements to improve product differentiation and regulatory positioning.
• Sustainability commitments drive investments in energy efficiency, green supply-chain practices, and potential carbon accounting/reporting upgrades.
• Quality-first manufacturing attracts institutional and export opportunities, supporting regulatory approvals in target markets.
• Integration of traditional herbal knowledge with evidence-based development supports both domestic consumer trust and international market access.

• Investors: R&D and sustainability targets signal long-term value creation, differentiation, and potential margin improvement from premium products.
• Consumers: Emphasis on natural, clinically-oriented Rhodiola products enhances brand trust and repeat purchase potential.
• Regulators/Partners: GMP compliance and evidence generation facilitate approvals and export partnerships.

Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) - Mission Statement

• Deliver clinically effective herbal formulations based on rhodiola and other traditional botanicals with verifiable quality and safety.
• Expand presence in North American and European markets through regulatory compliance, clinical studies, and international partnerships.
• Invest in R&D to innovate formulations and validate traditional uses with modern science.
• Operate with environmental responsibility, transparency, and traceable supply chains.

• Market expansion: targeted growth in North America and Europe to capture rising global demand for herbal supplements.
• Science-driven products: leveraging clinical research and manufacturing excellence to ensure efficacy and safety.
• Innovation commitment: directing ~10% of annual revenue to research and development for new formulations and clinical validation.
• Sustainability pledge: aiming for a 50% reduction in carbon footprint by 2030 through process improvements, energy transition, and supply-chain measures.
• Quality leadership: achieving recognized international certifications and regulatory approvals to support cross-border distribution.

• Global herbal supplement market valuation: approximately $121.6 billion in 2021.
• Projected industry growth: CAGR ~9.6% from 2022 to 2030, supporting demand in North America and Europe.
• Strategic fit: consumer preference for natural, evidence-backed supplements and increasing regulatory acceptance of traditional medicines in developed markets.

• Integrity - scientific rigor in validation and transparent reporting of product data.
• Tradition + Innovation - honoring Tibetan and Chinese herbal knowledge while applying modern pharmaceutical science.
• Quality - adherence to high manufacturing and quality-control standards for safety and efficacy.
• Sustainability - measurable environmental goals, including the 50% carbon reduction target by 2030.
• Global stewardship - responsible sourcing, community engagement, and ethical supply-chain practices.

Tibet Rhodiola Pharmaceutical Holding Co. (600211.SS) - Vision Statement

• Achieve a 50% reduction in carbon footprint by 2030 through energy efficiency, clean energy adoption, and supply-chain decarbonization.
• Allocate ~10% of annual revenue to R&D for new formulations, clinical studies, and process optimization to ensure product efficacy and regulatory compliance.
• Maintain vertical integration from sustainable Rhodiola harvesting to finished-product manufacturing and quality control to secure traceability and consistent supply.
• Expand market share domestically and internationally to capture growth in the global herbal supplement market, leveraging production scale and regulatory approvals.

Mission Statement

• Quality: implement GMP standards, batch-level testing, and full traceability across a vertically integrated supply chain.
• Innovation: invest in novel formulations and clinical validation to move traditional remedies into evidence-based therapeutics.
• Sustainability: prioritize habitat protection, community-based harvesting, and emissions reduction targets aligned with the 2030 goal.
• Accessibility: scale manufacturing and distribution to meet rising global demand for natural remedies and supplements.

Core Values and Strategic Metrics

Strategic Initiatives and Implementation

• Sustainable cultivation programs: community partnerships to ensure year-round Rhodiola supply while protecting alpine ecosystems.
• Carbon management: energy audits, switching to renewables at manufacturing sites, and optimized logistics to meet 2030 goal.
• R&D pipeline: clinical trials and formulation development funded via the ~10% revenue allocation to transition traditional extracts into validated products.
• Market expansion: regulatory dossiers and international distribution agreements to capture a share of the projected $121.6B-plus herbal supplement market.